01—Abstract
Summary
Summary of the 10-Q filed March 10, 2010. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported positive revenue and net income growth for the quarter ended January 31, 2010, signaling a potential recovery from the economic downturn.
Total net revenue increased by 4% year-over-year to $1,213 milliona, driven by strong performance in the Life Sciences and Chemical Analysis segments. Net income rose to $79 million from $64 million in the prior year period. The company is actively managing its portfolio through strategic initiatives, including the pending acquisition of Varian, Inc. for approximately $1.5 billion, which is progressing through regulatory approvals.
Agilent also announced the sale of its Network Solutions Division for $165 millionb. These strategic moves, coupled with ongoing restructuring efforts aimed at cost reduction, position Agilent for future growth and operational efficiency.
02—Key points
Key Highlights
- Total net revenue increased by 4% to $1,213 million for the quarter ended January 31, 2010, compared to the prior year period.
- Net income grew to $79 million ($0.22 per diluted share) from $64 million ($0.18 per diluted share) in the comparable prior year period.
- Orders increased by 9% year-over-year, indicating improving market conditions across key segments.
- Life Sciences and Chemical Analysis segments showed robust revenue growth of 10% and 13% respectively, with positive contributions from foreign currency movements.
- The company is proceeding with the proposed $1.5 billion acquisition of Varian, Inc., having received conditional antitrust clearance from the European Commission.
- Agilent continues to implement restructuring programs aimed at reducing operating expenses and improving efficiency, with remaining actions expected by Q2 2010.
- The company reported $30 million in cash from operations, an improvement from $17 million in the prior year quarter.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2010, Agilent Technologies, Inc. kept $0.07.
- Revenue$1.21B100.0%
- Cost of revenue−$553.0M45.6%
- Gross profit$660.0M54.4%
- Operating costs−$566.0M46.7%
- Operating income$94.0M7.7%
- Interest, other & tax−$15.0M1.2%
- Net income$79.0M6.5%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2010filed March 10, 2010Financial Statements
Q1 FY2010 against Q1 FY2009
| Line item | Q1 FY2010Q1 FY2009 | Change |
|---|---|---|
| Revenue | $1.21B$1.17B | +4.0% |
| Cost of Revenue | $553.00M$577.00M | −4.2% |
| Gross Profit | $660.00M$589.00M | +12.1% |
| R&D Expenses | $149.00M$169.00M | −11.8% |
| SG&A Expenses | $417.00M$396.00M | +5.3% |
| Operating Expenses | $1.12B— | — |
| Operating Income | $94.00M$24.00M | +291.7% |
| Interest Expense | -$23.00M— | — |
| Net Income | $79.00M$64.00M | +23.4% |
| EPS (Basic) | $0.23$0.18 | +27.8% |
| EPS (Diluted) | $0.22$0.18 | +22.2% |
| Shares Outstanding (Basic) | 348351 | −0.9% |
| Shares Outstanding (Diluted) | 354352 | +0.6% |
05—Questions
Frequently Asked Questions
What is the financial performance of Agilent Technologies for the quarter ended January 31, 2010?
Agilent Technologies reported a 4% increase in total net revenue to $1,213 million and a 23% increase in net income to $79 million for the quarter ended January 31, 2010, compared to the same period in the prior year. Orders also saw a 9% increase, indicating signs of market recovery.
What are the key strategic initiatives Agilent is undertaking?
The company is actively pursuing the acquisition of Varian, Inc., which is subject to regulatory approvals. Additionally, Agilent has agreed to sell its Network Solutions Division and is continuing with its restructuring programs to reduce operating expenses and enhance efficiency.
How is the pending acquisition of Varian, Inc. progressing?
The acquisition of Varian, Inc. for an estimated $1.5 billion is progressing. The European Commission has granted conditional antitrust clearance, and Agilent has committed to divest certain businesses as part of this clearance. Clearance from the U.S. Federal Trade Commission is still pending.
What is Agilent's outlook regarding market recovery?
Agilent's management observes signs of recovery in key markets, supported by the increase in orders and revenue. The company expects this recovery trend to continue, particularly in the Life Sciences and Chemical Analysis segments.
06—Continue